Elypta Overview

  • Status
  • Private
  • Employees
  • 12
Employees
  • Latest Deal Type
  • Later Stage VC
  • (Upcoming)
  • Investors
  • 8

Elypta General Information

Description

Developer of the first metabolism-based liquid biopsy platform designed to prevent cancer mortality through earlier detection and closer monitoring. The company's platform uses assay technology for comprehensive profiling of glycosaminoglycan metabolites, as well as scoring software for the broad potential across cancer indications with potential applications ranging from screening to response monitoring, enabling physicians to detect early-stage cancer when symptoms are inconclusive.

Contact Information

Website
www.elypta.com
Formerly Known As
Aurora Life Sciences
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Diagnostic Equipment
Other Industries
Other Healthcare Technology Systems
Decision/Risk Analysis
Discovery Tools (Healthcare)
Primary Office
  • Karolinska Institute
  • Nanna Svartz väg 4
  • 171 65 Solna
  • Sweden
+46 08-520 000 00

Elypta Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Elypta Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 31-Dec-2021 Upcoming Startup
6. Seed Round 01-Dec-2019 00.000 00.000 Completed Startup
5. Grant 15-Nov-2019 000.00 00.000 Completed Startup
4. Grant 01-Jan-2019 00.000 00.000 Completed Startup
3. Seed Round 11-Dec-2018 00000 00.000 Completed Startup
2. Seed Round 20-May-2018 $920K $920K Completed Startup
1. Grant 01-Jun-2016 $115K Completed Startup
To view Elypta’s complete valuation and funding history, request access »

Elypta Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of the first metabolism-based liquid biopsy platform designed to prevent cancer mortality through earlier dete
Diagnostic Equipment
Solna, Sweden
12 As of 2021
00.000
0000000000 0

0000000

sse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in
0000000000 000000000
Guangzhou, China
000 As of 0000
00000
000000000 00000

00000 00

tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitati
0000000000000
Baltimore, MD
00 As of 0000
00000
0000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Elypta Competitors (7)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Burning Rock Formerly VC-backed Guangzhou, China 000 00000 000000000 00000
00000 00000000000 Venture Capital-Backed Baltimore, MD 00 00000 00000000000 00000
000000 0000000 000 Formerly VC-backed Cambridge, MA 000 00000 000000&0 00000
00000 Formerly VC-backed Menlo Park, CA 000 000 000000&0 000
00000000 00000000 Venture Capital-Backed Shanghai, China 00 00000 00000000000 00000
You’re viewing 5 of 7 competitors. Get the full list »

Elypta Patents

Elypta Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3050203-A1 Cancer biomarkers Pending 07-Mar-2017 000000000000
AU-2018231421-A1 Cancer biomarkers Pending 07-Mar-2017 000000000000
US-20190391151-A1 Cancer biomarkers Pending 07-Mar-2017 000000000000
EP-3593139-A1 Cancer biomarkers Pending 07-Mar-2017 000000000000
JP-2020511643-A Cancer biomarker Pending 07-Mar-2017 G01N33/57407

Elypta Executive Team (4)

Name Title Board Seat Contact Info
Karl Bergman Chief Executive Officer
Johan Vikström Chief Financial Officer
Francesco Gatto Ph.D Co-Founder & Chief Scientific Officer
Jens Nielsen Co-Founder & Board Member
To view Elypta’s complete executive team members history, request access »

Elypta Board Members (5)

Name Representing Role Since
Anders Ekblom Ph.D Self Chairman 000 0000
Jens Nielsen Self Co-Founder & Board Member 000 0000
Jonas Jendi Industrifonden Board Member 000 0000
Pontus Ottosson Chalmers Ventures Board Member 000 0000
You’re viewing 4 of 5 board members. Get the full list »

Elypta Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Elypta Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Industrifonden Venture Capital Minority 000 0000 000000 0
Nina Capital Venture Capital Minority 000 0000 000000 0
Norrsken VC Venture Capital Minority 000 0000 000000 0
Sciety Venture Capital Minority 000 0000 000000 0
EIT Health Accelerator/Incubator Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »